B cell expansion and the production of autoantibodies by polyclonal B cell activation is a characteristic of RA [19], thus selective inhibition of Btk may be an attractive therapeutic target for B cell inhibition in RA as well as for B cell lymphoma. The gene discussed is BTK; the disease is rheumatoid arthritis.